Daily Newsletter

26 March 2024

Daily Newsletter

26 March 2024

Scivita Medical and Boston Scientific sign expanded cooperation arrangement

The collaboration is anticipated to facilitate the availability of Scivita Medical's products to more hospitals and patients.

Archana Rani March 26 2024

Scivita Medical Technology has expanded its strategic collaboration with Boston Scientific through a cooperation arrangement for endoscopic devices.

Under the arrangement, the two companies will focus on the co-development of future endoscopic devices and explore global distribution opportunities.

These activities are related to Scivita Medical’s single-use endoscope and imaging devices.

The expanded arrangement is anticipated to facilitate the availability of Scivita Medical's products to more hospitals and patients in China and other geographies globally.

Boston Scientific Endoscopy senior vice-president and president Mike Jones said: “We are excited to further our relationship with Scivita Medical which we anticipate will help provide physicians with more device options in geographies around the world.

“We look forward to successfully building on that relationship with this new arrangement.”

Scivita Medical is engaged in the research, development as well as commercialisation of medical endoscopes and related products.  

Scivita Medical co-founder, general manager and chief technology officer Dr Chin said: “This strengthened relationship will help us combine our core strengths and expertise to deliver high-quality single-use endoscope solutions to doctors and patients in various regions across the globe.

“Working with a company like Boston Scientific is crucial to Scivita Medical’s globalisation strategy.”

Last year, Scivita Medical signed an agreement with Boston Scientific for its single-use percutaneous choledochoscope.

At that time, Scivita Medical said the collaboration would further broaden the market penetration of its choledochoscope.

Recently, the US Food and Drug Administration (FDA) approved the Agent drug-coated balloon, which is developed by Boston Scientific, for the treatment of coronary in-stent restenosis (ISR), obstruction or narrowing of a stented vessel.

The Agent balloon can inflate to reopen the stent and diffuse paclitaxel – a chemotherapy drug that maintains the patency of the lumen of the blood vessel.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close